Congenital Anomalies in Newborns

I. Definition & Epidemiology

• WHO Definition: Structural, functional, or metabolic abnormalities present at birth, affecting 3-6% of live births globally.
• ICD-11 Codes: Ranging from LB00-LB9Y for accurate documentation.

II. Expanded Classification System

A. Structural Anomalies

1. Cardiovascular
   • Critical CHDs:
     • Hypoplastic Left Heart Syndrome (HLHS)
     • Tetralogy of Fallot (TOF)
   • Acyanotic: Ventricular Septal Defect (VSD), Patent Ductus Arteriosus (PDA)
2. Central Nervous System
   • Neural Tube Defects:
     • Anencephaly (fatal)
     • Spina Bifida (Myelomeningocele vs. Occulta)
   • Microcephaly (Zika virus association)
3. Craniofacial
   • Cleft Lip/Palate (Unilateral/Bilateral)
   • Craniosynostosis (Premature suture fusion)
4. Musculoskeletal
   • Clubfoot (Talipes Equinovarus)
   • Developmental Dysplasia of Hip (DDH)
5. Gastrointestinal
   • Omphalocele (Central defect, covered membrane)
   • Gastroschisis (Lateral defect, no membrane)

B. Functional/Developmental Anomalies

1. Metabolic Disorders
   • Phenylketonuria (PKU)
   • Congenital Hypothyroidism
2. Sensory
   • Congenital Cataracts
   • Sensorineural Hearing Loss
3. Chromosomal Abnormalities

III. Etiological Framework 

• Syndromic (Genetic: Trisomies, Turner)
• Teratogenic (Alcohol, Valproate)
• Organ-specific (Isolated defects)
• Random (De novo mutations)
• Known environmental (Maternal diabetes, infections)

IV. Advanced Diagnostic Modalities

1. Prenatal
   • First Trimester: Combined test (NT ultrasound + β-hCG/PAPP-A)
   • Second Trimester: Quad screen + Fetal echocardiography
   • Emerging: Cell-free DNA analysis (NIPT)
2. Postnatal
   • Whole Exome Sequencing (WES)
   • Metabolic Screens (Tandem MS/MS)

V. Management Protocols by System

A. Cardiac Anomalies

• Duct-Dependent Lesions: Prostaglandin E1 infusion
• Surgical Timing:
  • Palliative (e.g., BT shunt for TOF)
  • Corrective (e.g., VSD closure at 3-6mo)

B. Neural Tube Defects

• Myelomeningocele:
  • Surgical closure <72h
  • VP shunt for hydrocephalus

C. Metabolic Disorders

• PKU: Phe-restricted diet initiated <2wks

VI. Prevention Strategies

• Primary: Folic acid 4mg/day (pre-conception)
• Secondary: Early anomaly scans (11-14w, 18-22w)
• Tertiary: Neonatal surgery/medical therapy

VII. Prognostic Indicators

• Favorable: Isolated defects (e.g., cleft lip)
• Guarded: Complex CHDs, trisomies
• Poor: Lethal anomalies (e.g., Thanatophoric dysplasia)

VIII. Parent Counseling Guide

1. Diagnosis Disclosure:
   • Use "SPIKES" protocol (Setting, Perception, Invitation, Knowledge, Empathy, Summary)
2. Long-Term Planning:
   • Early Intervention Programs (OT/PT)
   • Transition to adult care for survivable conditions

IX. Emerging Therapies

• Fetal Surgery: For spina bifida (MOMS trial criteria)
• Gene Therapy: ADA-SCID treatment

Clinical Pearls

1. "Timing Rule":
   • Teratogen exposure at 3-8w → Cardiac/CNS defects
   • Exposure at 8-12w → Palate/genital anomalies
2. Red Flags for Genetic Testing:
   • Multiple anomalies
   • Dysmorphic features
   • Family history
3. Documentation Tip:
   • Always specify "isolated" vs "syndromic" in diagnoses